CLVSF (CellaVision AB) Debt-to-Asset : 0.04 (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB Debt-to-Asset?

CellaVision AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.00 Mil. CellaVision AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.46 Mil. CellaVision AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $96.18 Mil. CellaVision AB's debt to asset for the quarter that ended in Sep. 2024 was 0.04.

CellaVision AB Debt-to-Asset Historical Data

The historical data trend for CellaVision AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Debt-to-Asset Chart

CellaVision AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.27

0.20

0.17

0.12

0.07

CellaVision AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.07	0.06	0.05	0.04

Competitive Comparison of CellaVision AB's Debt-to-Asset

For the Medical Devices subindustry, CellaVision AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CellaVision AB's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Debt-to-Asset falls into.

CellaVision AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CellaVision AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.513	+	2.794)	/	90.539
	=	0.07

CellaVision AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.995	+	1.464)	/	96.181
	=	0.04

CellaVision AB (OTCPK:CLVSF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CellaVision AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CellaVision AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CEVI:Sweden 0MR5:UK C26:Germany

Address

Mobilvagen 12, Lund, SWE, 22362

Website

https://www.cellavision.com

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.